A Phase 2 interventional study of Administration of L-TC and HFRT alone in Sarcoma, sponsored by Centre Paul Strauss. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by Centre Paul Strauss · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 175 studies in Sarcoma with a site in France — 49 open to participants now, 63 under way, 8 of them phase 3. Sarcoma · France.
Among the 175 studies in Sarcoma with a site in France, this one is the 128th largest by planned enrollment of the 152 interventional ones that give a count, is one of 6 that started in 2026, is one of 51 in phase 2, reaches primary completion later than 42 of the 62 other live ones, and was the 158th registered.
1,610 studies on the registry are indexed under Sarcoma; 367 are open to participants now.
Browse Sarcoma studies →49 of the 175 studies in Sarcoma with a site in France are open now. Recruiting first, the newest first:
Institut Bergonié · Sites in France
Ages 15–49
Centre Oscar Lambret · Sites in France
Ages 18+
GlaxoSmithKline · Sites in France, United States, Canada and 3 more countries
University Hospital, Strasbourg, France · Sites in France
Ages 18+
Novartis Pharmaceuticals · Sites in France, United States, Canada and 4 more countries
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 302 Sarcoma studies recruiting now, 192 (64%) set no upper age limit and 83 (27%) stop at 75 or younger; 94 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
175 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 79 · Phase 3 31 · Phase 4 2
First in 1988; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 42 is close to the median of 41 across 1,255 interventional studies indexed under Sarcoma.
Median enrollment 115 across the 152 interventional studies, 254 across the 22 observational. Of the 103 that completed or were terminated, 32 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
61 of 175 have an industry lead sponsor. The 10 most frequent:
Centre Paul Strauss is the lead sponsor of 31 studies on the registry; 21 are open to participants now.
Centre Paul Strauss has 1 study filed under Sarcoma — fewer than ten, so there is no comparison to draw.
14 of the studies in Sarcoma with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03805022Phase 3Institut BergoniéBenefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas | 2026-12 |
| NCT02789384Institut BergoniéCINSARC Signature and Correlation With Hemotherapy Efficacy in Soft-tissue Sarcomas. A Biomarker Study. | 2026-12 |
| NCT05182164Institut BergoniéCombination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas | 2026-12 |
| NCT02838602Hospices Civils de LyonRandomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors | 2026-12-23 |
| NCT03474094Centre Leon BerardClinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy | 2026-12-30 |
Add all 14 to your calendar (.ics) → With an account.
Among the 175 studies in Sarcoma with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is phase II randomized, multicenter study of treatment with L-TC and preoperative HFRT in patients who were aged 18 years or older with documented localised or locally advanced soft-tissue sarcoma of the extremity.
Eligible patients will be randomly assigned 2:1 to receive a preoperative HFRT alone (Arm A) or L-TC with preoperative HFRT (Arm B).
This is a non-comparative phase II trial (comparison is made regarding a reference, not 2 between 2 proportions). Considering the wide confidence interval retrieved in literature regarding pCR value with HFRT, pCR value used in the sample size calculation and taken from the literature must be included in the 95% CI of the pCR from the control group.
The PRACTISS trial aims to improve treatment outcomes for patients with extremity STS by incorporating Liposomal Transcrocetin (L-TC) with Hypofractionated Radiotherapy (HFRT). L-TC is designed to enhance tumor oxygenation, addressing hypoxia-a significant factor contributing to radioresistance. By reoxygenating tumor cells, L-TC may improve radiosensitivity, increasing the efficacy of radiotherapy and leading to higher rates of pathological complete response (pCR) before surgery. Achieving a higher pCR is associated with better long-term outcomes and reduced recurrence rates. Additionally, the use of HFRT reduces the overall treatment schedule compared to conventional radiotherapy, minimizing the treatment burden for patients and potentially improving their quality of life while maintaining treatment effectiveness.
L-TC 300 mg QD, administered as intravenous infusion over 90 minutes, at a fixed dose of 300 mg daily before each HFRT fraction, for a total of 5 days corresponding to the planned five daily HFRT fractions. The intravenous infusion should start 120 minutes before each HFRT fraction. Radiotherapy is scheduled to coincide with the plasma peak, which occurs approximately 2 hours after the start of the infusion
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
L-TC as an IV infusion over 90 minutes at a fixed dose of 300 mg daily before each HFRT fraction, for a total of 5 days corresponding to the planned five daily HFRT fractions. The intravenous infusion should begin 2 hours before each HFRT fraction. Radiotherapy is scheduled to coincide with the plasma peak, which occurs approximately 2 hours after the start of the infusion. + HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.
Drug: Administration of L-TC
HFRT treatment will be administered in control group as 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.
Radiation: HFRT alone
Administration of L-TC (300 mg) as an IV perfusion, daily before each radiotion session
HFRT : 30 Gy in 5 fractions of 6 Gy. 1 fraction per day, 5 days per week.
Evaluation of the efficacy of the L-TC treatment in combination with preoperative hypofractionated radiotherapy (HFRT)
Pathological complete response rate (pCR): defined as the presence of \< 10% residual malignant viable cells.
Time frame: At surgery (Between 4 and 8 weeks after the end of radiotherapy)
Evaluation of the acute tolerance o f L-TC
Toxicities and biological analysis before each injection of L-TC and before surgery, described by type and grade, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 classification
Time frame: Up to day 5 (every day during the treatment)
Evaluation of the late tolerance o f L-TC
Toxicities and biological analysis before each injection of L-TC and before surgery, described by type and grade, using the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 classification
Time frame: Up to day 28 after the end of treatment.
Evaluation of the acute tolerance of radiotherapy
Global tolerance (radiotherapy toxicities (oedema, radiodermatitis, fibrosis, bone fracture) and laboratory abnormalities) at each physician consultation for radiotherapy and at follow-up, using the CTCAE v.5.0 classification
Time frame: Up to day 5 (every day during the treatment)
Evaluation of the late tolerance of radiotherapy
Global tolerance (radiotherapy toxicities (oedema, radiodermatitis, fibrosis, bone fracture) and laboratory abnormalities) at each physician consultation for radiotherapy and at follow-up, using the CTCAE v.5.0 classification
Time frame: at 4 months after surgery, and at 12, 18, 24, 36 and 60 months
Evaluation of tumour necrosis
Proportion of patient whom tumor has pathologic necrosis on histologic examination
Time frame: At surgery (Between 4 and 8 weeks after the end of radiotherapy)
Evaluation of the radiological response
Proportion of patients with a complete or partial radiological response (according to RECIST 1.1) evaluated on MRI
Time frame: at screening and before surgery
Proportion of patients with R0 resection
Number of patients with R0 resection on the number of enrolled patients
Time frame: At surgery
Evaluation of the Local Progression-Free Survival (L-PFS)
L-PFS will be defined as the length of time from the date of diagnostic by biopsy to the date of local relapse on MRI. L-PFS will be determined in median and rate
Time frame: at 12, 24, 36 and 60 months.
Evaluation of the Distant Progression-Free Survival (D-PFS)
D-PFS will be defined as the length of time from the date of diagnostic by biopsy to the date of distant relapse on scanner. D-PFS will be determined in median and rate
Time frame: at 12, 24, 36 and 60 months.
Evaluation of the Overall Survival (OS)
OS will be defined as the length of time from the date of diagnostic by biopsy to the date of death, whatever the cause. Patients will be censored on the last news date. OS will be determined in median and rate
Time frame: at 12, 24, 36 and 60 months
Evaluation of the Quality of Life (QoL)
Use of the European Organisation for Research and Treatment of Cancer (EORTC) 30-Item Core Quality of Life Questionnaire (QLQ-C30)
Time frame: at the inclusion (baseline) and every 4 months the two first years and then every 6 months the next three years
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jul 2026; primary completion for Oct 2028, 27 months later.
Of 198 non-industry phase 2 interventional studies under Sarcoma, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 46 and three quarters within 91. This study's planned 27 months is below that.
Counting every sponsor, half of 227 studies reached it within 66 months; a quarter within 43 and three quarters within 92.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Paul Strauss